Healthcare / BiotechnologyNasdaqGM
$3.83
-0.08 (-2.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-49.5M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$229M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-98.4%
↓Gross Margin
99.4%
↑Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-147.7%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $33.5M · net income $-52.7M · FCF $-49.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $33.5M | $33.5M | $2.6M | $2.8M | $3.5M | — | — |
| Net Income | $-52.7M | $-52.7M | $-61.0M | $-49.1M | $-33.6M | $-378753.00 | — |
| EBITDA | $-51.2M | $-51.2M | $-64.0M | $-51.2M | $-32.4M | — | — |
| EPS | — | — | -1.66 | -1.48 | -1.06 | -0.02 | — |
| Gross Margin | 99.4% | 99.4% | 92.3% | 93.3% | 94.0% | — | — |
| Operating Margin | -154.7% | -154.7% | -2437.5% | -1866.2% | -924.3% | — | — |
| Net Margin | -157.4% | -157.4% | -2313.3% | -1779.7% | -951.3% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.30 | 0.30 | 0.50 | 0.02 | 0.23 | — | — |
| Current Ratio | 7.03 | 7.03 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-49.5M | $-49.5M | $-50.8M | $-46.2M | $-29.9M | — | — |
| Returns | |||||||
| ROE | -98.4% | -98.4% | -185.2% | -72.2% | -64.0% | 9.6% | — |
| Valuation | |||||||
| P/B | 4.08 | 4.08 | 6.47 | 3.64 | 6.04 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 1169.2% | 1169.2% | -4.4% | -21.9% | — | — | — |
| EPS Growth | — | — | -12.2% | -39.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.66 → n/d
Residual
+34.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.